Biomerica, Inc. (NASDAQ:BMRA) Sees Significant Drop in Short Interest

Biomerica, Inc. (NASDAQ:BMRA) saw a large decline in short interest in the month of March. As of March 31st, there was short interest totalling 66,500 shares, a decline of 13.3% from the March 15th total of 76,700 shares. Based on an average trading volume of 59,100 shares, the short-interest ratio is presently 1.1 days.

Biomerica Stock Down 4.1 %

Shares of Biomerica stock traded down $0.03 during trading on Tuesday, reaching $0.74. 63,942 shares of the company traded hands, compared to its average volume of 84,702. Biomerica has a 1-year low of $0.70 and a 1-year high of $2.13. The company has a 50 day moving average price of $0.99 and a 200-day moving average price of $0.97.

Biomerica (NASDAQ:BMRA) last released its quarterly earnings data on Friday, April 12th. The company reported ($0.11) earnings per share for the quarter. Biomerica had a negative return on equity of 59.76% and a negative net margin of 117.46%. The business had revenue of $1.02 million for the quarter.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Jane Street Group LLC bought a new stake in shares of Biomerica in the 1st quarter worth $57,000. Penn Capital Management Company LLC bought a new stake in shares of Biomerica in the 1st quarter worth $50,000. Geode Capital Management LLC grew its stake in shares of Biomerica by 16.4% in the 4th quarter. Geode Capital Management LLC now owns 90,817 shares of the company’s stock worth $304,000 after acquiring an additional 12,811 shares in the last quarter. Russell Investments Group Ltd. grew its stake in shares of Biomerica by 4.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 181,687 shares of the company’s stock worth $247,000 after acquiring an additional 7,414 shares in the last quarter. Finally, Boothbay Fund Management LLC bought a new stake in shares of Biomerica in the 1st quarter worth $481,000. Institutional investors and hedge funds own 22.28% of the company’s stock.

Biomerica Company Profile

Biomerica, Inc, a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations.